Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Outcome analysis of liraglutide versus other antidiabetic medications in type 2 diabetes

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: CHANG, Hsiu-Mei (Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Department of Pharmacy)
  • Co-author(s): Hsiu-Mei Chang: Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Jiun-Shiuan He: Department of Management, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Kun-Der Lin: Division of Endocrinology & Metabolism, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Yen-Huei (Tony) Tarn: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Ying-Chi Lin: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  • Abstract:

    Background

    Liraglutide is a glucagon-like peptide-1(GLP-1) receptor agonist approved for the treatment of type-2 diabetes mellitus (T2DM). Despite of high cost, liraglutide gradually become popular in our hospital since its availability in 2012.

    Methods

    A retrospective cohort study in adult patients diagnosed with T2DM was conducted using database

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses